Monoclonal Antibodies

 
 
 

Immunotherapy

Haematologic Malignancies

Solid Organ Malignancies

Other

 
 
Login or Register to unlock everything MedSchool has to offer!
 
 

Anti-HER2 Antibodies

 
 
  •  
    IV infusion / Subcut
    Trastuzumab
    Herceptin 
     
    Inhibits ligand-independent HER signalling
  •  
    IV infusion
    Pertuzumab
    Inhibits ligand-dependent HER2 dimerisation and signalling
    • Mechanism of Action
    • Monoclonal antibodies directed against the HER2 receptor, which is involved in cell signalling and is overexpressed in certain cancers. Inhibition of HER2 signalling pathways results in cell cycle arrest; the monoclonal antibody also mediates antibody-dependent cell-mediated cytotoxicity.
Clinical Use
    • Indications
    • HER2 positive breast cancer
    • HER2 positive advanced gastric cancer (trastuzumab)
    • Contraindication
    • Left ventricular dysfunction, as evidenced by an LVEF <45%, or symptomatic heart failure (trastuzumab).
    • Adverse Effects
    • Cardiac dysfunction
    • Bone marrow suppression – leucopaenia, anaemia, thrombocytopaenia
    • Immunosuppression (susceptibility to infection)
    • Nausea / vomiting / diarrhoea
    • Abdominal pain
    • Dyspnoea / wheeze
    • Peripheral neuropathy
    • Arthralgias / myalgias
    • Headache
    • Dizziness
    • Flushing
    • Weight loss
    • Insomnia
    • Rash
 
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
 
Read More...
Feedback